FORM 10 - Q
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549
(Mark one)
( X )        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
             SECURITIES EXCHANGE ACT OF 1934

             For the quarterly period ended: September 30, 1997
                                       OR
(   )        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
             SECURITIES EXCHANGE ACT OF 1934

             For the transition period from

Commission file Number:  0-22212

                              IVI PUBLISHING, INC.

                          (Exact Name of Registrant as
                            specified in its charter)

        Minnesota                                          41-1686038
 (State or other jurisdiction of            (IRS Employer Identification No.)
  incorporation or organization)

                             7500 Flying Cloud Drive
                        Minneapolis, Minnesota 55344-3739

                    (Address of principal executive offices)
                                   (Zip Code)

                                  612-996-6000

              (Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                       Yes      X           No

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

         Class                               Outstanding as of November 5, 1997
        Common Stock                                10,105,475 shares
        Par Value $.01 Per Share


<PAGE>

                              IVI PUBLISHING, INC.

                  Securities and Exchange Commission Form 10-Q
                 for the Third Quarter Ended September 30, 1997

                                      INDEX



PART I.  FINANCIAL INFORMATION:

Item 1.       Financial Statements

              Condensed Statements of Operations  (Unaudited) Three months ended
              September  30, 1997 and  September  30,  1996;  Nine months  ended
              September 30, 1997 and September 30, 1996

              Condensed Balance Sheets September 30, 1997
              (Unaudited) and December 31, 1996

              Condensed  Statements of Cash Flows  (Unaudited) Nine months ended
              September 30, 1997 and September 30, 1996

              Notes to Condensed Financial Statements (Unaudited)

Item 2.       Management's Discussion and Analysis of Financial
              Condition and Results of Operations

Item 3.       Quantitative and Qualitative Disclosures About Market Risk

PART II.  OTHER INFORMATION:

Item 1.       Legal Proceedings
Item 2.       Changes in Securities and Use of Proceeds
Item 3.       Defaults Upon Senior Securities
Item 4.       Submission of Matters to a Vote of Security Holders
Item 5.       Other Information
Item 6.       Exhibits and Reports on Form 8-K

SIGNATURES



<PAGE>
                          PART I. FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

IVI Publishing, Inc.
Condensed Statements of Operations  (Unaudited)
(In thousands except per share data)
<TABLE>
<CAPTION>

                                      Three Months Ended    Nine Months Ended
                                         September 30         September 30
                                      ------------------    ------------------
                                       1997       1996       1997       1996
                                      -------    -------    -------    -------


<S>                                       <C>        <C>        <C>        <C>
Net revenues                          $   488    $ 2,249    $ 2,731    $ 7,003
Cost of revenues                          311      1,090      1,347      3,525
                                      -------    -------    -------    -------

Gross margin                              177      1,159      1,384      3,478

Costs and expenses:
      Product development                 378      1,574      2,779      4,610
      Sales and marketing                 333        679        976      2,078
      General and administrative        2,096      2,834      5,702      5,052
                                      -------    -------    -------    -------

Loss from operations                   (2,630)    (3,928)    (8,073)    (8,262)
Other income                            2,704                 2,704
Interest (expense) income                 (68)        28       (184)       177
                                      -------    -------    -------    -------

Net income (loss)                     $     6    ($3,900)   ($5,553)   ($8,085)
                                      =======    =======    =======    =======

Preferred stock dividends             ($   30)   ($   30)   ($   90)   ($   90)
Preferred stock accretion                 (13)       (13)       (39)       (39)
                                      -------    -------    -------    -------

Net loss applicable to common stock   ($   37)   ($3,943)   ($5,682)   ($8,214)
                                      =======    =======    =======    =======

Net loss per common share             ($ 0.00)   ($ 0.52)   ($ 0.74)   ($ 1.08)
                                      =======    =======    =======    =======

Weighted average number of common
shares outstanding                      7,618      7,608      7,636      7,580
                                      =======    =======    =======    =======

</TABLE>


See notes to condensed financial statements.
<PAGE>


IVI Publishing, Inc.
Condensed Balance Sheets
(In thousands)
<TABLE>
<CAPTION>
                                                      September 30  December 31
                                                            1997        1996
                                                        --------    --------
                                                      (Unaudited)
<S>                                                    <C>          <C>
Assets
Current assets:
      Cash and cash equivalents                         $  2,788    $  3,462
      Accounts receivable, net                               437       4,134
      Inventory                                              301         155
      Other current assets                                   417         585
                                                        --------    --------
Total current assets                                       3,943       8,336

Furniture and equipment                                    6,663       6,812
Less allowances for depreciation                          (4,399)     (3,622)
                                                        --------    --------
                                                           2,264       3,190

Other non-current assets                                     738       1,885

                                                        ========    ========
Total assets                                            $  6,945    $ 13,411
                                                        ========    ========

Liabilities and Shareholders' Equity
Current liabilities:
      Accounts payable                                  $  3,443    $  3,635
      Other accrued expenses                                 333       1,471
                                                        --------    --------
Total current liabilities                                  3,776       5,106

Convertible subordinated debentures                        3,500       3,500
Convertible redeemable preferred stock                     1,944       1,905

Shareholders' equity:
      Common Stock, $.01 par value:
         Issued and outstanding shares-
         7,348 at September 30, 1997 
         and 7,612 at December 31, 1996                       73          76
      Paid-in capital                                     70,834      70,453
      Accumulated deficit                                (73,182)    (67,629)
                                                        --------    --------
Total shareholders' (deficit) equity                      (2,275)      2,900
                                                        --------    --------

Total liabilities and shareholders' (deficit) equity    $  6,945    $ 13,411
                                                        ========    ========

</TABLE>

See notes to condensed financial statements.

<PAGE>

IVI Publishing, Inc.
Condensed Statements of Cash Flows  (Unaudited)
(In thousands)
<TABLE>
<CAPTION>


                                                                         Nine Months Ended September 30
                                                                         ------------------------------                
                                                                               1997       1996
                                                                              -------    -------
Operating activities
<S>                                                                           <C>        <C>
      Net loss                                                                ($5,553)   ($8,085)
      Adjustments to reconcile net loss to net cash used in
         operating activities:
         Depreciation and amortization                                            984      1,059
         Stock issued for litigation settlement                                   433
      Changes in assets and liabilities:
         Decrease (increase) in net accounts receivable                         3,697       (394)
         (Increase) decrease in inventories                                      (146)       400
         Decrease (increase) in other current assets                              168        (18)
         Decrease (increase) in other long-term assets                          1,103       (641)
         (Decrease) increase in accounts payable and
              accrued liabilities                                              (1,420)       634
                                                                              -------    -------

      Net cash used in operating activities                                      (734)    (7,045)

Investing activities
      Net furniture and equipment (additions) disposals                           (14)       342
                                                                              -------    -------

      Net cash (used) provided by investing activities                            (14)       342

Financing activities
      Proceeds from exercised stock options                                        74        347
                                                                              -------    -------

      Net cash provided by financing activities                                    74        347

Net decrease in cash and cash equivalents                                        (674)    (6,356)
                                                                                           
Cash and cash equivalents at beginning of period                                3,462      7,759
                                                                              -------    -------

Cash and cash equivalents at end of period                                    $ 2,788    $ 1,403
                                                                              =======    =======

</TABLE>

See notes to condensed financial statements.


<PAGE>


                              IVI Publishing, Inc.
             Notes to the Condensed Financial Statements (Unaudited)
                               September 30, 1997


Note A -- Basis of Presentation

The accompanying  unaudited condensed financial statements have been prepared in
accordance with generally accepted  accounting  principles for interim financial
information and with the  instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly,  they do not include all information and footnotes required by
generally accepted accounting principles for complete financial  statements.  In
the opinion of  management,  all  adjustments  (consisting  of normal  recurring
accruals)  considered  necessary  for a fair  presentation  have been  included.
Operating  results for the nine month  period ended  September  30, 1997 are not
necessarily  indicative  of the results  that may be expected for the year ended
December 31, 1997. For further information,  refer to the consolidated financial
statements and footnotes thereto included in the Company's annual report on Form
10-K for the year ended December 31, 1996.

Note B -- Product Development Costs

Product  development  costs  consist  principally  of  compensation  to  Company
employees,  interactive  design  costs paid to outside  consultants,  travel and
supplies. All costs are expensed as incurred.

Costs  related to research,  design and  development  of products are charged to
product  development   expenses  as  incurred.   Under  Statement  of  Financial
Accounting  Standards  No.  86 (SFAS No.  86),  software  development  costs are
capitalized  beginning  when a  product's  technological  feasibility  has  been
established  and  ending  when a product is  available  for  general  release to
customers.  The Company has not capitalized any software development costs since
such costs meeting the requirements of SFAS No. 86 have not been significant.

Note C -- Net Loss Per Share

Net loss per share is computed  using the weighted  average  number of shares of
common  stock  outstanding.  Common  equivalent  shares  from stock  options and
warrants are excluded from the computation as their effect is anti-dilutive.

In February 1997, the Financial  Accounting Standards Board issued Statement No.
128,  "Earnings Per Share." This statement  establishes  standards for computing
and  presenting  basic  and  diluted  earnings  per share  (EPS)  for  financial
statements  issued for periods  ending after  December 15, 1997. The adoption of
this statement will not have a material effect on the Company's reported EPS.



<PAGE>



Note D -- Revenue Recognition

The Company's revenues consist of product sales and licensing revenue,  contract
development  revenue,  fees  relating to the licensing of its content for use on
cable television, and fees for online services.

Product sales and licensing revenues are made up of retail  distribution  sales,
direct  mail  sales,  and product  sales and  royalties  on licenses to original
equipment  manufacturers.  These  revenues are  recognized  upon shipment of the
product or when the Company's  obligations  under the licensing  agreements  are
complete. Allowances for returns are recorded at the time revenue is recognized.

Contract  development  revenue is  generated  through  the use of the  Company's
personnel and facilities for the creation of custom  multimedia  products.  This
revenue is  recognized by contract on a  percentage-of-completion  basis or at a
specific hourly rate, depending on the terms of the contract.

Revenues are generated through the licensing of the Company's health and medical
content for use on cable television  channels.  The Company  recognizes  revenue
under its cable agreement ratably over the life of the contract.

Revenues are generated  through the sale of sponsorships  and advertising on the
Company's web site.  These revenues are recognized as they are earned.  Revenues
were also generated through the Company's online agreement with AT&T in 1996.

Note E -- Litigation Settlements

During the third quarter,  the Company settled a lawsuit with Viridis,  Inc. for
$350,000 cash and 175,000 shares of the Company's  stock.  The stock will not be
registered  and is restricted  under Rule 144 of the Securities Act of 1933. The
shares were expensed at their estimated value at the settlement date, $433,125.

In November  1997, a jury  verdict was  rendered in a case  brought  against the
Company by T. Randal Productions,  Inc. in February 1996. The jury award was for
$480,000. The Company recorded this amount as an expense in September 1997.

Note F -- Mayo Agreement

In August  1997,  the Company  entered into an  agreement  with Mayo  Foundation
("Mayo")  which includes a full transfer of ownership of IVI's O@sis web site to
Mayo and a new arrangement for revenues and cost sharing concerning O@sis. Under
the  terms  of the  agreement,  IVI  received  a  $2,700,000  cash  payment,  an
additional  $300,000  cash  payment for  hosting  the web site for a  transition
period,  490,000 shares of IVI stock and the Company will receive a royalty from
Mayo on certain  revenues  generated  by the Mayo Health  O@sis site and certain
other non-O@sis  Internet projects through the year 2001. In addition,  Mayo was
released  from the  Company's  "right of first  offer" on Mayo  health  products
produced for electronic  media, and Mayo assumed all operating  expenses for the
web site  retroactive  to January 1, 1997.  The Company  recorded the $2,700,000
payment  as other  income,  reversed  previously  recorded  product  development
expenses,  and recorded most of the $300,000 payment as deferred  income,  which
will be recognized over the fourth quarter as the transition period expires.

Note G -- Subsequent Event

In October 1997, the  Convertible  Subordinated  Debentures and the  Convertible
Redeemable Preferred Stock were converted to common stock at a rate of $2.00 per
share, resulting in the issuance of 2,750,000 shares of common stock.


<PAGE>


ITEM 2.  Management's Discussion and Analysis
of Financial Condition and Results of Operations

Overview

The  Company's  strategy  for the rest of 1997 and  beyond  continues  to be the
establishment  of the Company as the leading  provider of health  information to
consumers and businesses via multiple media channels  including online,  CD-ROM,
and  cable  television.  The  OnHealth  web  site  is an  integral  part of this
strategy. During the third quarter of 1997, the Company expanded its presence in
the online market by signing multiple sponsorship and advertising agreements for
the OnHealth site.  These  contracts  began  generating  revenue for the Company
during the second  half of the third  quarter.  In the  future,  in  addition to
increasing  sponsorship  and advertising  revenues,  the Company expects to earn
commissions on products sold over the web site.

During the third  quarter,  the Company also finalized a new agreement with Mayo
Clinic and as a result has a very limited role in the future  production  of the
Mayo Health O@sis web site.  The Company  received $2.7 million as  compensation
for a full transfer of ownership of the O@sis web site to Mayo and for releasing
Mayo of its  obligation  to give the Company the "right of first  offer" on Mayo
products  published in electronic  media. The Company also received  $300,000 as
compensation  for continuing to host the Mayo O@sis web site during a transition
period. In addition, the Company has the right to receive a royalty from Mayo on
certain  revenues  generated  by the Mayo Health  O@sis site and  certain  other
non-O@sis  Internet projects through the year 2001. The new agreement allows the
Company to focus the majority of its sales, marketing and development efforts on
its OnHealth web site and the Company intends to use the cash received from Mayo
to fund this strategy.

The  Company  has  continued  to focus its CD-ROM  efforts on its family  health
reference  CD-ROM  titles.  During  September,  the Company  launched the second
version of its flagship CD-ROM product,  Mayo Clinic Ultimate  Medical Guide II,
which consists of the updated versions of the Mayo Clinic Family Health Book and
the Mayo Clinic Family Pharmacist discs packaged as a single unit.  Although the
Company's  strategy calls for more of a focus on the online market,  the Company
will continue to publish its family health reference CD-ROM titles.

The Company has continued to generate revenue through contract development work,
and  plans to do so in the  future.  Part of the  Company's  strategy  calls for
aligning the Company with  strategic  partners who desire  contract  development
work for health information  content that the Company can use to enhance its own
web site.


<PAGE>



Results Of Operations

Net income for the third quarter of 1997 totaled $6,000,  compared to a net loss
of $3,900,000 for the third quarter of 1996.  Third quarter income was partially
due to the  $2,700,000  of other  income  that was  recognized  when the Company
transferred  its ownership and control of the Mayo Health O@sis web site to Mayo
Foundation.

Net revenues were $488,000 for the third quarter of 1997, compared to $2,249,000
for the same period of 1996. The revenues were comprised as follows:


                                        Third Quarter Third Quarter
                                              1997         1996
                                          ----------   ----------
                                          ----------   ----------

CD-ROM Retail                             $  193,000   $  387,000
CD-ROM OEM and License                        58,000      938,000
Contract Development                         191,000      370,000
Online Revenue                                37,000
Amortization of Cable Royalty                             493,000
Other Revenue                                  9,000       61,000
                                          ----------   ----------
                                          ----------   ----------

Total Net Revenues                        $  488,000   $2,249,000
                                          ==========   ==========

The  decrease  in  revenues  resulted in part from the  Company's  inability  to
recognize any cable royalty revenues.  This is due to America's Health Network's
("AHN") failure to obtain financing and honor its contract  obligations with the
Company  by the end of the  third  quarter;  however,  AHN is  still  diligently
seeking  financing which would allow it to honor its obligations to the Company.
Additionally,  CD-ROM  retail and OEM revenues  decreased  due to the  Company's
decision to shift its focus to its online efforts.

Gross  margins as a percentage  of net  revenues for the third  quarter and nine
months ended September 30, 1997 were 36% and 51%, respectively,  compared to 52%
and 50% for the  comparable  periods of 1996. A significant  decrease in margins
earned on contract  development  work during the third  quarter  contributed  to
reduced  margins;  however,  the gross  margins  earned on  revenues to date are
comparable to the prior year.

Product development  expenses were $378,000 and $2,779,000 for the third quarter
and nine months ended September 30, 1997,  respectively,  compared to $1,574,000
and $4,610,000 for the comparable periods in 1996. The decrease resulted in part
from  the  Company's  new  arrangement  with  Mayo  Foundation.  Under  the  new
agreement,  Mayo  assumed all  operating  expenses for the Mayo Health O@sis web
site,  retroactive  to January 1, 1997. The operating  costs,  which the Company
recorded  during  the first  half of the year,  were  reversed  during the third
quarter,  after the agreement was signed.  Also, the Company realized additional
cost savings by concentrating its development  efforts on its OnHealth web site,
which incurs fewer development costs than CD-ROMs.

Sales  and  marketing  expenses  for the third  quarter  and nine  months  ended
September  30,  1997  were  $333,000  and  $976,000  compared  to  $679,000  and
$2,078,000  for the  comparable  periods of 1996.  The decrease was due to fewer
consulting and promotional expenses paid on CD-ROM sales. The Company intends to
focus its sales and marketing force on online opportunities, while continuing to
maintain its CD-ROM sales.

<PAGE>

General and  administrative  expenses  decreased in the third quarter of 1997 to
$2,096,000 compared to $2,834,000 for the third quarter of 1996. However,  these
expenses  increased  for the nine months ended  September  30, to  $5,702,000 in
1997,  as  compared  to  $5,052,000  in 1996.  The  overall  increase  is due to
extensive legal fees incurred  throughout  1997 for lawsuits with Viridis,  Inc.
and T. Randal Productions, Inc. The former was settled during the third quarter,
and the latter went to trial with a verdict  being entered by a jury in November
1997 (See Note E).  General and  administrative  expenses for the third  quarter
1996 included several one time charges including a loss recorded on the sublease
of office space and employee severance charges totaling  $978,000.  In addition,
there was a write-off of a $836,000 receivable to bad debt expense.

Net interest  expense was $68,000 and  $184,000  for the third  quarter and nine
months ended September 30, 1997,  compared to net interest income of $28,000 and
$177,000 for the same periods in 1996.  The decrease  resulted  from having less
cash available for investing  purposes  combined with interest  expense payments
made on the Company's convertible subordinated debentures,  which were issued in
November 1996.

Financial Condition, Liquidity and Capital Resources

Capital asset  expenditures  for the nine month period ended  September 30, 1997
totaled $65,000 and consisted  principally of computer equipment.  Capital asset
disposals totaled $51,000.

At  September  30,  1997,  the  Company had cash and cash  equivalents  totaling
$2,788,000.  Total cash used during the nine months ended September 30, 1997 was
$674,000.  The Company believes that its current working capital and anticipated
operating  cash  flows  will  be  sufficient  to  fund  its  operations  for the
foreseeable future. These assumptions are based on the Company maintaining costs
and significantly  increasing revenues.  The increase in revenues is expected to
come  from the sale of site  sponsorships,  advertising,  and  commissions  from
product sales on the Company's web site. Any material reduction in the projected
revenues  would  likely  require the Company to seek  additional  equity or debt
financing.  There is no assurance  that such  financing will be available or, if
available, whether the financial terms would be reasonable.

In October 1997, the  Convertible  Subordinated  Debentures and the  Convertible
Redeemable  Preferred  Stock were  converted to common  stock,  resulting in the
issuance of 2,750,000 shares of common stock.

The Company has an asset of $675,000 that  represents  the remaining  portion of
the costs paid, net of royalties received and write-offs, to Time Life, Inc. for
the  development  of the print  version of Taking  Control of Your  Health.  The
Company will  continue to amortize this asset as royalties on sales of the print
version  are  received  from  Time  Life,  Inc.  There  are  certain  risks  and
uncertainties  in assuming  that the sales  volume of the print  version will be
sufficient  to fully  amortize  this  asset;  however,  based on the most recent
review  of  this  asset,  management  believes  the  remaining  balance  will be
realizable.  Management  will  continue to review  this  asset's  valuation  for
impairment.

This  report  contains  forward-looking  statements  that are subject to certain
risks and  uncertainties  that could cause actual  results to differ  materially
from those projected. Specifically, statements relating to expected increases in
revenues from web site  sponsorship,  advertisement  and commissions on products
sold over the web site; royalties on revenues generated by the Mayo Health O@sis
site,  revenues  arising from contract  development  work,  and  sufficiency  of
working  capital depend,  among other things,  on successful  negotiations  with
third  parties,  and  consumer  demand for the  information  that the  Company's
OnHealth web site provides.


ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

Not required for this filing.


<PAGE>
                            PART II OTHER INFORMATION


ITEM 1.           LEGAL PROCEEDINGS

In March  1996,  the Company  commenced  an action  seeking  replevin of certain
computer equipment leased to a former contractor,  Viridis. In May 1996, Viridis
expanded the scope of the action by filing a cross-complaint against the Company
alleging that the Company breached contractual obligations and committed various
torts by ending its business  relationship with Viridis and seeking $10 million.
In October  1997,  the Company and Viridis  entered into a settlement  agreement
resolving all disputes between them. IVI made an initial payment of $225,000 and
is paying  $125,000  in 15 monthly  installments  ending in December  1988,  and
issued 175,000 shares of restricted IVI common stock to Viridis'  designee at an
estimated value of $433,125.  An additional $25,000 is due if IVI's AHN payments
resume.

In February 1996, an action in the District Court of Hennepin County (Minnesota)
was brought by T. Randal  Productions et al. against the Company and one current
and two former  employees.  The plaintiffs made various  allegations,  including
misappropriation of corporate opportunities and trade secrets by the Company and
its  employees  and sought  award of  monetary  damages,  exemplary  damages and
royalties  substantially  in excess of $10.0  million.  In October  1997, a jury
found that there was no joint venture  between T. Randal and the Company  and/or
any of its employees but awarded T. Randal $480,000 for damages sustained to its
business.  The jury  verdict  is subject  to  motions  for a new trial,  amended
findings and for judgment notwithstanding the verdict and to appeal to the Court
of Appeals.

In 1996,  Berkshire  Multimedia Group, Inc.  ("Berkshire")  initiated  mediation
regarding a dispute with the Company.  Shortly after an  unsuccessful  mediation
conference was held in September 1996,  Berkshire filed a demand for arbitration
alleging  that  the  Company  breached  its  obligations  under a  contract.  An
arbitration  hearing was  completed in January  1997,  and in February  1997 the
arbitration  panel  awarded  Berkshire  $300,000.  Hennepin  County  (Minnesota)
District  Court  vacated that award on May 29, 1997,  and Berkshire has appealed
the case.  The appeal was recently heard by the court of Appeals but no decision
has yet been rendered.

ITEM 2.           CHANGES IN SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.           DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5.           OTHER INFORMATION

In October 1997, the  Convertible  Subordinated  Debentures and the  Convertible
Redeemable Preferred Stock were converted to common stock at a rate of $2.00 per
share, resulting in the issuance of 2,750,000 shares of common stock.

ITEM 6.           EXHIBITS AND REPORTS ON FORM 8-K

(a)    The following exhibits are included herein:

         (10.1)   Settlement  Agreement and Mutual  Release dated  September 12,
                  1997  between  the  Company  and Mayo  Foundation  for Medical
                  Education and Research.

         (10.2)   Sublicense  Agreement  dated  September  12, 1997  between the
                  Company  and  Mayo   Foundation  for  Medical   Education  and
                  Research.

         (11)     Computation  of per share loss.

         (27)     Financial Data Schedule (included only in electronic version).

(b)    No reports on Form 8-K were filed by the Company during the quarter ended
       September 30, 1997

<PAGE>

                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                   IVI PUBLISHING, INC.


                                   By /s/  Charles A. Nickoloff
                                   Charles A. Nickoloff
                                   Vice President and
                                   Acting Chief Financial Officer

Date:  November 7, 1997